Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01171105 · ClinicalTrials.gov registry record · Phase 1
Study to Investigate Multiple Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 73
- Enrollment target
NCT01171105 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 73 participants.
The verdict
NCT01171105, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 73 participants
- Enrollment target
Study Summary
1. The main purpose of this study is to assess the safety and tolerability of AZD5213 after multiple oral doses. 2. Another purpose of this study is to evaluate the pharmacokinetics (also called PK - how the study drug enters and leaves your body and how your body acts on the study drug) of AZD5213 in your blood and urine.
Interventions
- DRUG AZD5213
- DRUG Placebo to AZD5213
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01171105
The ClinicalTrials.gov registry entry for NCT01171105 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AZD5213 is the first listed.
NCT01171105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01171105 about?
NCT01171105 is a clinical study titled "Study to Investigate Multiple Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects". 1. The main purpose of this study is to assess the safety and tolerability of AZD5213 after multiple oral doses. 2. Another purpose of this study is to evaluate the pharmacokinetics (also called PK - how the study drug enters and leaves your body and how your body acts on the study drug) of AZD5213 ...
What is the current status of trial NCT01171105?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2010-07. Estimated completion is 2011-05.
What interventions are being tested in trial NCT01171105?
The interventions under investigation include: AZD5213 (DRUG), Placebo to AZD5213 (DRUG).
Who is sponsoring clinical trial NCT01171105?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.